ArticleCancer research communications2026
Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PD-1/PD-L1 immune checkpoint inhibitor (ICI)-based combination regimens have transformed metastatic urothelial cancer treatment. However, phase III trials of these regimens have shown varied results. We sought to understand these differences by assessing whether these combinations are synergistic, additive, or less-than-additive, which is crucial for translational research and clinical development. We systematically identified five randomized phase III trials of ICI-based combinations for metastatic urothelial carcinoma and tested whether progression-free survival (PFS) distributions of combinations were as predicted by a null hypothesis of additivity, defined as the sum of PFS durations of individual drugs. For KEYNOTE-361 and IMvigor130, which allowed cisplatin or carboplatin, we evaluated platinum-specific predictions. We found that PFS distributions in trials adding PD-1/PD-L1 ICI to enfortumab vedotin (EV-302), gemcitabine plus cisplatin (CheckMate 901), or CTLA-4 blockade (DANUBE) were statistically indistinguishable from additivity. In trials using choice of cisplatin or carboplatin (KEYNOTE-361, IMvigor130), ICI combinations with cisplatin-gemcitabine yielded additive PFS, whereas ICI combinations with carboplatin-gemcitabine yielded less-than-additive PFS, indicating that carboplatin blunts the potential benefits of PD-1/PD-L1 inhibitors. The predictable success of EV-302 and CheckMate 901 demonstrate that substantial improvements in clinical outcomes can be achieved by additive combinations of individually effective agents. Overall, modeling PFS from single-agent data could have anticipated most contemporary phase III trial outcomes, potentially informing rational trial design and prioritization. SIGNIFICANCE: Practice-changing PD-1/PD-L1 immune checkpoint combinations in urothelial cancer show additive, not synergistic, efficacy in phase III trials. However, carboplatin was significantly less-than-additive with immunotherapy, helping explain negative results of KEYNOTE-361 and IMvigor130.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.